Literature DB >> 18628404

The alpha1D-adrenergic receptor induces vascular smooth muscle apoptosis via a p53-dependent mechanism.

Mary L García-Cazarín1, Jennifer L Smith, Daret K St Clair, Michael T Piascik.   

Abstract

Activation of the endogenous alpha1-adrenergic receptor (AR) associated with human aortic smooth muscle cells resulted in a dose- and time-dependent increase in the levels of mitochondrial reactive oxygen species (ROS). ROS increases were apparent within 10 min and maximal after 45 min. Prolonged activation (>4 h) of the alpha1-AR resulted in smooth muscle cell apoptosis. Both the increase in ROS and apoptotic cell death were blocked by the nonselective alpha1-AR antagonist prazosin as well as the selective alpha1D-AR antagonist 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7, 9-dione (BMY 7378). Increases in ROS and apoptosis produced by alpha1-AR activation were also blocked by the p38 mitogen-activated protein kinase inhibitor 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole (SB 202190) and the NAPDH oxidase inhibitor apocynin. The extracellular signal-regulated kinase 1/2 inhibitor 2'-amino-3'-methoxyflavone (PD 98059) or the c-Jun NH2-terminal kinase inhibitor 1, 9-pyrazoloanthrone anthra(1, 9-cd)pyrazol-6(2H)-one (SP 600125) was without effect on increases in ROS levels or apoptosis. Pifithrin-alpha, an inhibitor of the tumor suppressor protein p53, had no effect on ROS generation but did block alpha1D-AR-induced apoptosis. Activation of the alpha1D-AR resulted in translocation of p53 to the mitochondria. The mitochondrial translocation of p53 was blocked by prazosin, BMY 7378, apocynin, SB 202190, and pifithrin-alpha. Apoptosis was also blocked by small interfering RNA directed against p53. These data show that the alpha1D-AR is coupled to the generation of mitochondrial ROS by a pathway involving p38 and NADPH oxidase. Sustained activation of the alpha1D-AR results in smooth muscle cell apoptosis in a pathway that involves the tumor suppressor protein p53 and the mitochondrial translocation of p53. The data also provide evidence of a linkage between the alpha1D-AR and p53.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18628404     DOI: 10.1124/mol.108.047993

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  6 in total

Review 1.  Use of inotropes and vasopressor agents in critically ill patients.

Authors:  Mansoor N Bangash; Ming-Li Kong; Rupert M Pearse
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Vascular smooth muscle insulin resistance, but not hypertrophic signaling, is independent of angiotensin II-induced IRS-1 phosphorylation by JNK.

Authors:  Hirofumi Hitomi; Puja K Mehta; Yoshihiro Taniyama; Bernard Lassègue; Bonnie Seidel-Rogol; Alejandra San Martin; Kathy K Griendling
Journal:  Am J Physiol Cell Physiol       Date:  2011-09-07       Impact factor: 4.249

3.  LOX-1, mtDNA damage, and NLRP3 inflammasome activation in macrophages: implications in atherogenesis.

Authors:  Zufeng Ding; Shijie Liu; Xianwei Wang; Yao Dai; Magomed Khaidakov; Xiaoyan Deng; Yubo Fan; David Xiang; Jawahar L Mehta
Journal:  Cardiovasc Res       Date:  2014-04-28       Impact factor: 10.787

4.  The superoxide dismutase mimetic tempol does not alleviate glucocorticoid-mediated rarefaction of rat skeletal muscle capillaries.

Authors:  Erin R Mandel; Emily C Dunford; Ghoncheh Abdifarkosh; Patrick C Turnbull; Christopher G R Perry; Michael C Riddell; Tara L Haas
Journal:  Physiol Rep       Date:  2017-05

5.  Mediators of human ureteral smooth muscle contraction-a role for erythropoietin, tamsulosin and Gli effectors.

Authors:  Kymora B Scotland; Samir Bidnur; Lu Wang; Ben H Chew; Dirk Lange
Journal:  Transl Androl Urol       Date:  2021-07

6.  Evaluation of apoptosis indexes in currently used oral alpha-blockers in prostate: a pilot study.

Authors:  Mehmet Demir; Yigit Akin; Kubra Asena Kapakin Terim; Mehmet Gulum; Evren Buyukfirat; Halil Ciftci; Ercan Yeni
Journal:  Int Braz J Urol       Date:  2018 May-Jun       Impact factor: 1.541

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.